Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

FDA approves, Immunex launches breakthrough treatment for RA

Nov. 3, 1998

Orally active collagenase inhibitor Ro-32-3555 shows potential for osteoarthritis Rx

Nov. 3, 1998

Preparation and use of TNF-alpha and MMP inhibitors described by Novartis

Nov. 3, 1998

Safety and efficacy of COX-2 inhibitor established in phase II trials

Nov. 2, 1998

Prosorba Column recommended for approval by FDA advisory panel

Nov. 2, 1998

Vertex and HMR initiate phase I clinical trial with HMR-3480/VX-740

Oct. 30, 1998

New COX-2 inhibitor scheduled for FDA advisory committee review in early December

Oct. 30, 1998

Preparation and pharmaceutical formulations of nimesulide choline salt claimed by Dompe

Oct. 27, 1998

Anika receives nonapprovable letter from FDA for Orthovisc

Oct. 22, 1998

Synvisc approved for treatment of osteoarthritis in Argentina and Brazil

Oct. 20, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...